Acute Unilateral NAION following Tirzepatide Therapy: A Case Report
Case Reports in Ophthalmology · 18.06.2026 · 17 (1) · 806-813
DOI: 10.1159/000552569 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Ophthalmology, online erschienen am 18.06.2026. Verfasst von Jela Valášková und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, such as tirzepatide, have significantly advanced the management of type 2 diabetes mellitus and obesity. However, emerging safety signals have raised concerns regarding rare ocular adverse events. Case Presentation: We report a case of an obese patient undergoing treatment with tirzepatide who presented with progressive, painless visual loss in the left eye 2 weeks after symptom onset. Four weeks prior to presentation, she had initiated tirzepatide therapy for weight reduction at a dose of 15 mg once weekly without standard dose titration. Best-corrected visual acuity was 20/20 in the right eye and counting fingers at 1 meter in the left eye. Fundus examination revealed hyperemic optic disc oedema with peripapillary flame-shaped haemorrhages. Automated perimetry demonstrated a central scotoma. MRI of the brain and orbits excluded intracranial pathology and showed no optic nerve enhancement. Intravenous methylprednisolone was administered, after which visual acuity improved to 20/40.
Conclusion
Regulatory and pharmacovigilance data suggest that NAION may represent a very rare adverse event associated with GLP-1 receptor agonists, with observational studies indicating a possible association for tirzepatide, although absolute risk appears low and causality remains unproven. While the relationship between dual GIP/GLP-1 receptor agonists and NAION remains controversial, clinicians – particularly ophthalmologists – should remain vigilant and consider this potential risk when evaluating the benefit-risk profile for individual patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
Zitieren
APA
Valášková, J., Bondarchuk, D., Kadlic, P., Kaššová, T., & Plesniková, P. (2026). Acute Unilateral NAION following Tirzepatide Therapy: A Case Report. Case Reports in Ophthalmology, 17(1), 806-813. https://doi.org/10.1159/000552569
Vancouver
Valášková J, Bondarchuk D, Kadlic P, Kaššová T, Plesniková P. Acute Unilateral NAION following Tirzepatide Therapy: A Case Report. Case Reports in Ophthalmology. 2026;17(1):806-813. doi:10.1159/000552569
BibTeX
@article{Valkov2026,
author = {Valášková, Jela and Bondarchuk, Dmytro and Kadlic, Peter and Kaššová, Terézia and Plesniková, Paulina},
title = {Acute Unilateral NAION following Tirzepatide Therapy: A Case Report},
journal = {Case Reports in Ophthalmology},
year = {2026},
volume = {17},
number = {1},
pages = {806--813},
doi = {10.1159/000552569}
}
EUVIMED